(-0.07%) 5 474.50 points
(-0.10%) 38 778 points
(-0.04%) 19 914 points
(0.20%) $80.49
(1.33%) $2.83
(0.22%) $2 334.10
(-0.19%) $29.34
(-0.21%) $968.90
(0.02%) $0.932
(-0.14%) $10.64
(0.07%) $0.788
(-1.86%) $86.81
@ $16.67
Išleistas: 17 birž. 2024 @ 22:06
Grąža: -0.60%
Ankstesnis signalas: birž. 14 - 17:30
Ankstesnis signalas:
Grąža: 0.54 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
Šios dienos apimtis | 1.54M |
Vidutinė apimtis | 3.00M |
Rinkos kapitalizacija | 2.56B |
EPS | $-0.0732 ( Q1 | 2024-05-06 ) |
Kita pelno data | ( $0 ) 2024-07-30 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
55.23 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0200 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
82.20 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
Tūris Koreliacija
TG Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
TG Therapeutics Inc Koreliacija - Valiuta/Žaliavos
TG Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $233.66M |
Bruto pelnas: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2023 |
Pajamos: | $233.66M |
Bruto pelnas: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2022 |
Pajamos: | $2.79M |
Bruto pelnas: | $2.52M (90.48 %) |
EPS: | $-1.510 |
FY | 2021 |
Pajamos: | $6.69M |
Bruto pelnas: | $5.90M (88.19 %) |
EPS: | $-2.63 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.